Interleukin-18 as an efficient marker for remission and follow-up in patients with inactive adult-onset Still's disease

Scandinavian Journal of Rheumatology

Volumn 43, Issue 2, 2014, Pages 162-169

  Jung, K H ^a   Kim, J J ^b   Lee, J S ^b   Park, W ^a   Kim, T H ^b   Jun, J B ^b   Yoo, D H ^b  

^a Inha University Hospital   (South Korea)

^b Hanyang University Hospital for Rheumatic Diseases   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; GAMMA INTERFERON; INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ADULT ONSET STILL DISEASE; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MARKER; FEMALE; FOLLOW UP; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-18; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REMISSION INDUCTION; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STILL'S DISEASE, ADULT-ONSET;

EID: 84895749354     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2013.824023     Document Type: Article

References (24)

1. Efthimiou P, Paik PK, Bielory L. Diagnosis and management of adult onset Still's disease. Ann Rheum Dis 2006;65:564-72
2. Fautrel B. Adult-onset Still disease. Best Pract Res Clin Rheumatol 2008;22:773-92
3. Chen DY, Lan JL, Lin FJ, Hsieh TY. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. J Rheumatol 2004;31:2189-98
4. Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol 2003;73:213-24
5. Boraschi D, Dinarello CA. IL-18 in autoimmunity: Review. Eur Cytokine Netw 2006;17:224-52
6. KawashimaM, Yamamura M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, et al. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum 2001;44:550-60
7. Kawaguchi Y, Terajima H, Harigai M, Hara M, Kamatani N. Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still's disease. Arthritis Rheum 2001;44:1716-17
8. Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M. Interleukin-18 binding protein: A novel modulator of the Th1 cytokine response. Immunity 1999;10:127-36
9. Hurgin V, Novick D, Rubinstein M. The promoter of IL-18 binding protein: Activation by an IFN-gamma-induced complex of IFN regulatory factor 1 and CCAAT/enhancer binding protein beta. Proc Natl Acad Sci USA 2002;99:16957-62
10. Novick D, Schwartsburd B, Pinkus R, Suissa D, Belzer I, Sthoeger Z, et al. A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine 2001;14:334-42
11. Mazodier K, Marin V, Novick D, Farnarier C, Robitail S, Schleinitz N, et al. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood 2005;106:3483-9
12. Novick D, Elbirt D, Miller G, Dinarello CA, Rubinstein M, Sthoeger ZM. High circulating levels of free interleukin-18 in patients with active SLE in the presence of elevated levels of interleukin-18 binding protein. J Autoimmun 2010;34:121-6
13. Ianello A, Boulassel MR, Samarani S, Tremblay C, Toma E, Routy JP, et al. HIV-1 causes an imbalance in the production of interleukin-18 and its natural antagonist in HIV-infected individuals: Implications for enhanced viral replication. J Infect Dis 2010;201:608-17
14. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992;19:424-30
15. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24
16. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8
17. Pouchot J, Sampalis JS, Beaudet F, Carette S, Décary F, Salusinsky-Sternbach M, et al. Adult Still's disease: Manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore) 1991;70:118-36
18. Kim SH, Eisenstein M, Reznikov L, Fantuzzi G, Novick D, Rubinstein M, et al. Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci USA 2000;97:1190-5
19. Shimizu C, Fujita T, Fuke Y, Ito K, Satomura A, Matsumoto K, et al. High circulating levels of interleukin-18 binding protein indicate the severity of glomerular involvement in systemic lupus erythematosus. Mod Rheumatol 2012;22:73-9
20. Fautrel B, Le Moel G, Saint-Marcoux B, Taupin P, Vignes S, Rozenberg S, et al. Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease. J Rheumatol 2000;28:322-9
21. Shimizu M, Nakagishi Y, Kasai K, Yamasaki Y, Miyoshi M, Takei S, et al. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-Associated macrophage activation syndrome: The diagnostic significance of interleukin-18 and interleukin-6. Cytokine 2012;58:287-94
22. Yoshida Y, Sakamoto M, Yokota K, Sato K, Mimura T. Tocilizumab improved both clinical and laboratory manifestations except for interleukin-18 in a case of multiple drug-resistant adultonset Still's disease. Intern Med 2011;50:1757-60
23. Nagashima T, Iwamoto M, Matsumoto K, Minota S. Interleukin-18 in adult-onset Still's disease: Treatment target or disease activity indicator? Intern Med 2012;51:449
24. Jung SY, Park YB, Ha YJ, Lee KH, Lee SK. Serum calprotectin as a marker for disease activity and severity in adult-onset Still's disease. J Rheumatol 2010;37:1029-34